Testing TQC3927 inhalation powder for COPD

A Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of Single/Multiple Dose Escalation of TQC3927 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease

This study is testing a new inhalation powder called TQC3927 to see if it can help people with COPD breathe better and improve their lung function.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (estimated)
• Ages: 40 Years to 70 Years
• Sex: All
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Industry-sponsored)
• Locations: 7 sites (Beijing, Beijing and 6 other locations)
• Trial ID: NCT06711991 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the safety, tolerability, and pharmacokinetics of TQC3927 powder for inhalation in patients with Chronic Obstructive Pulmonary Disease (COPD). It is a multi-center, randomized, double-blind, placebo-controlled study that includes both single and multiple dose assessments. The trial aims to determine the appropriate dosing and effects of the medication on lung function. Participants will undergo reproducible lung function testing to assess the drug's impact.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 45 with a diagnosis of COPD who meet specific lung function and health criteria.

Not a fit: Patients with a history of certain medical conditions or those who have recently participated in other clinical trials may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could improve lung function and quality of life for patients with COPD.

How similar studies have performed: Other studies have shown promise in using inhalation therapies for COPD, but the specific approach with TQC3927 is novel.

Eligibility criteria

Inclusion Criteria:

* Between 18 and 45 years (inclusive)，both male and female
* The subjects were able to undergo reproducible FEV1 lung function testing according to the American Thoracic Society/European Respiratory Society (ATS/ERS) 2005 standard during screening
* Subject should weigh at least 45kg. And body mass index (BMI) within 18\~30 kg/m2
* Have no pregnancy plan and voluntarily take effective contraception measures from time of screening to at least 90 days after the last dose (subjects and their partners)

Exclusion Criteria:

* Patients with a history of glaucoma, functional constipation, prostate hyperplasia, urinary tract obstruction, etc
* Individuals with a history of illegal drug abuse or who have tested positive for drug abuse screening during the screening period (including benzodiazepines, methamphetamine, cocaine, morphine, ketamine, tetrahydrocannabinol)
* Participated in other clinical trials and received research interventions in the 3 months prior to participating in this trial
* Screening for individuals who have used biologics within the past 3 months
* Individuals who have lost blood or donated more than 400 mL of blood within 3 months prior to the experiment, or who have received blood transfusions or used blood products
* Any clear history of drug or food allergies, especially those who are allergic to ingredients similar to the investigational drug
* Screening for individuals who have frequently consumed alcohol within the previous 6 months (i.e. females consume more than 14 standard units of alcohol per week, males consume more than 21 standard units of alcohol per week (1 standard unit contains 14g of alcohol, such as 360 mL beer or 45 mL of 40% alcohol strong liquor or 150 mL wine) or are unable to abstain from alcohol during the trial period; Or those who test positive for alcohol breath test
* History of any malignant tumors in organs or systems within the past 5 years, regardless of whether they have received treatment or not, except for local basal cell carcinoma of the skin
* When screening, the sitting systolic blood pressure should be ≥ 160 mmHg, and the sitting diastolic blood pressure should be ≥ 100 mmHg; Pulse rate\<50 bpm or\>100 bpm
* Clinically significant apnea patients requiring continuous positive airway pressure (CPAP) or non-invasive positive airway pressure (NIPPV) devices
* Those who require long-term oxygen therapy (oxygen therapy time\>15 hours/day)
* Individuals who have undergone lobectomy or lung volume reduction surgery within the 12 months prior to the start of the study

Where this trial is running

Beijing, Beijing and 6 other locations

• China Japan Friendship Hospital — Beijing, Beijing, China (Recruiting)
• Aerospace Center Hospital — Beijing, Beijing, China (Not_yet_recruiting)
• The First Affiliated Hospital of Nanchang University — Nanchang, Jiangxi, China (Not_yet_recruiting)
• Heze Municipal Hospital — Heze, Shandong, China (Not_yet_recruiting)
• Zibo Municipal Hospital — Zibo, Shandong, China (Not_yet_recruiting)
• The Third People Hospital of Chengdu — Chengdu, Sichuan, China (Not_yet_recruiting)
• The Second Affiliated Hospital of Wenzhou Medical University — Wenzhou, Zhejiang, China (Not_yet_recruiting)

Study contacts

• Study coordinator: Ting Yang, Doctor

Conditions Chronic Obstructive Pulmonary Disease